⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0287

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2023-01-27
Adverse events
8
Serious AEs
3
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-26 (study day 10); relationship: Y

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-04 (study day 47); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 88); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-05-20 (study day 93); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-26 (study day 160); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-01 (study day 227); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-13 (study day 270); relationship: Y; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 284); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.